PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2770890-2 1989 The slices were preincubated with 3H-5-HT 0.1 mumol/l in the presence of the irreversible MAO inhibitor pargyline 50 mumol/l and then continuously superfused. Pargyline 104-113 monoamine oxidase A Rattus norvegicus 90-93 2532443-4 1989 By using both a monoamine oxidase (MAO) inhibitor (pargyline) and a serotonin precursor, 5-hydroxytryptophan rather than L-tryptophan, with or without an inhibitor of serotonin synthesis, p-chlorophenylalanine, we have demonstrated that many LC neurons have the capacity to accumulate serotonin and not other indoleamines. Pargyline 51-60 monoamine oxidase A Rattus norvegicus 35-38 3213579-2 1988 Pargyline (75 mg/kg, s.c.), a monoamine oxidase (MAO) inhibitor, was administered 30 min prior to decapitation. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 30-47 3139835-2 1988 The MAO inhibitors pargyline, clorgyline, and deprenyl all yielded biphasic competition curves versus [3H]tryptamine. Pargyline 19-28 monoamine oxidase A Rattus norvegicus 4-7 2842890-4 1988 Clorgyline and pargyline were used as inhibitors of monoamine oxidase (MAO) A and B, respectively. Pargyline 15-24 monoamine oxidase A Rattus norvegicus 52-83 2907098-3 1988 When MAO activity was inhibited by pargyline (10 mumol/l), p-tyramine and p-octopamine had mixed excitatory-inhibitory effects on the twitches, while noradrenaline had mostly excitatory effects along the whole range of concentrations assayed (0.158-15.8 mumol/l). Pargyline 35-44 monoamine oxidase A Rattus norvegicus 5-8 2455784-3 1988 When the MAO inhibitor pargyline was injected and the animals killed at different times, there was an exponential decrease in the concentration of 5-hydroxyindole acetic acid (5-HIAA) with time, whereas the increase in 5-hydroxytryptamine was linear only during the first 30 min, thereafter reaching a plateau. Pargyline 23-32 monoamine oxidase A Rattus norvegicus 9-12 3213579-2 1988 Pargyline (75 mg/kg, s.c.), a monoamine oxidase (MAO) inhibitor, was administered 30 min prior to decapitation. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 49-52 3148140-4 1988 Pargyline did not increase the reinforcement rate at low doses that selectively inhibit MAO-B, but did increase the reinforcement rate at doses that inhibit MAO-A by more than 90%. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 157-162 3664088-8 1987 In vitro treatment with the monoamine oxidase (MAO) inhibitors, iproniazid or pargyline, did not potentiate responses to either noradrenaline or isoprenaline. Pargyline 78-87 monoamine oxidase A Rattus norvegicus 28-45 3664088-8 1987 In vitro treatment with the monoamine oxidase (MAO) inhibitors, iproniazid or pargyline, did not potentiate responses to either noradrenaline or isoprenaline. Pargyline 78-87 monoamine oxidase A Rattus norvegicus 47-50 3683592-3 1987 The extraneuronal COMT activity was determined under conditions of inhibition of both neuronal uptake and MAO (pretreatment with pargyline). Pargyline 129-138 monoamine oxidase A Rattus norvegicus 106-109 2886556-4 1987 Molecular forms of MAO were examined by using specific MAO inhibitors, and by polyacrylamide gel electrophoresis after [3H]pargyline binding. Pargyline 123-132 monoamine oxidase A Rattus norvegicus 19-22 3780861-7 1986 pargyline produced equivalent inhibition of rat brain MAO and decreased the binding of [3H]clonidine and [3H]RX 781094 to the alpha 2-adrenoceptor and of [3H]dihydroalprenolol to the beta-adrenoceptor without changing binding of [3H]prazosin to the alpha 1-adrenoceptor. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 54-57 3790166-1 1986 The concentrations of monoamine oxidase-A and -B have been determined in mitochondria, mitochondrial outer membranes and microsomes from Sprague-Dawley and Wistar rats by determining the binding of tritium-labelled pargyline. Pargyline 215-224 monoamine oxidase A Rattus norvegicus 22-48 2442302-2 1987 The disappearance of 5-HTOL following monoamine oxidase (MAO) inhibition induced by pargyline was more rapid (t1/2 10-15 min) than that of 5-HIAA (t1/2 30-40 min) in all regions investigated, indicating a rapid turnover of 5-HTOL. Pargyline 84-93 monoamine oxidase A Rattus norvegicus 38-55 2442302-2 1987 The disappearance of 5-HTOL following monoamine oxidase (MAO) inhibition induced by pargyline was more rapid (t1/2 10-15 min) than that of 5-HIAA (t1/2 30-40 min) in all regions investigated, indicating a rapid turnover of 5-HTOL. Pargyline 84-93 monoamine oxidase A Rattus norvegicus 57-60 3668521-1 1987 The treatment of Sprague-Dawley rats with monoamine oxidase (MAO) inhibitors (pargyline, tranylcypromine) profoundly affects dopamine (DA) and norepinephrine (NE) metabolism in the brain. Pargyline 78-87 monoamine oxidase A Rattus norvegicus 42-59 3668521-1 1987 The treatment of Sprague-Dawley rats with monoamine oxidase (MAO) inhibitors (pargyline, tranylcypromine) profoundly affects dopamine (DA) and norepinephrine (NE) metabolism in the brain. Pargyline 78-87 monoamine oxidase A Rattus norvegicus 61-64 3574494-2 1987 The animals had been treated with the MAO inhibitor pargyline (40 mg/kg) 30 min before i.c.v. Pargyline 52-61 monoamine oxidase A Rattus norvegicus 38-41 3697783-3 1986 Inhibition of DA inactivation processes by local application of benztropine (a DA reuptake inhibitor, 10(-6) M) or by IV administration of pargyline (a MAO inhibitor, 100 mg/kg) enhanced the detectable outflow of 3H-DA from the striatum in both halothane anesthetized and awake rats. Pargyline 139-148 monoamine oxidase A Rattus norvegicus 152-155 3091132-5 1986 Repeated but not single treatment with the nonselective and irreversible MAO inhibitors nialamide and pargyline reduced markedly the ejaculatory response but only slightly the 5-HT behavioural responses. Pargyline 102-111 monoamine oxidase A Rattus norvegicus 73-76 3762740-6 1986 Determinations of the activity of MAO in homogenates of vasa deferentia showed that preincubation with 10 and 20 nmol/l pargyline inhibited the enzyme by 80 to 95%. Pargyline 120-129 monoamine oxidase A Rattus norvegicus 34-37 3730457-1 1986 Behavioral depression produced by exposing animals to a stressor that they cannot control (uncontrollable shock) was reversed by infusion of the monoamine oxidase (MAO) inhibitor pargyline into the locus coeruleus (LC) region of the brain stem. Pargyline 179-188 monoamine oxidase A Rattus norvegicus 145-162 3730457-1 1986 Behavioral depression produced by exposing animals to a stressor that they cannot control (uncontrollable shock) was reversed by infusion of the monoamine oxidase (MAO) inhibitor pargyline into the locus coeruleus (LC) region of the brain stem. Pargyline 179-188 monoamine oxidase A Rattus norvegicus 164-167 3930664-3 1985 However, in rats previously treated with the MAO inhibitors pargyline or tranylcypromine, the same L-DOPA or free DA treatment resulted in significant increases in both 3-MT and DA sulfate in the hypothalamus, brainstem, and striatum. Pargyline 60-69 monoamine oxidase A Rattus norvegicus 45-48 3990515-5 1985 In contrast, the inhibitory effect of PEA on the LC neurons was strongly potentiated by pretreatment with the selective monoamine oxidase (MAO) - B inhibitor pargyline (2 mg/kg, i.p., 1 h), but, unexpectedly, also by pretreatment with the MAO-A selective inhibitors clorgyline (2 mg/kg, i.p., 1 h) or FLA 336 (2 mg/kg, i.p., 1 h). Pargyline 158-167 monoamine oxidase A Rattus norvegicus 239-244 4058679-6 1985 Pargyline was a relatively more potent inhibitor of MAO than chlordimeform, but not more efficacious. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 52-55 3929190-1 1985 Pargyline, an inhibitor of monoamine oxidase (MAO), prevented 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced inhibition of dihydroxyphenylalanine (DOPA) production by tyrosine hydroxylase (TH) system in rat striatal tissue slices. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 27-44 3929190-1 1985 Pargyline, an inhibitor of monoamine oxidase (MAO), prevented 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced inhibition of dihydroxyphenylalanine (DOPA) production by tyrosine hydroxylase (TH) system in rat striatal tissue slices. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 46-49 3871853-4 1985 dose antagonized the irreversible inactivation of MAO-A in rat brain by pargyline, indicating that it inhibited MAO-A in vivo. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 50-55 3872699-0 1985 Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]pargyline binding to monoamine oxidase. Pargyline 94-103 monoamine oxidase A Rattus norvegicus 115-132 3872699-4 1985 Under the conditions of the assay, [3H]pargyline labeled the type B form of MAO. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 76-79 3839173-8 1985 Pargyline and tranylcypromine shifted the dose-response curves for tyramine and beta-phenylethylamine, but not serotonin, to the left, indicating inhibition of type B MAO. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 167-170 3871853-4 1985 dose antagonized the irreversible inactivation of MAO-A in rat brain by pargyline, indicating that it inhibited MAO-A in vivo. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 112-117 6542783-0 1984 [Inhibition of monoamine oxidase A and B in the heart and brain of the rat with amitriptyline, pargyline and pirlindol]. Pargyline 95-104 monoamine oxidase A Rattus norvegicus 15-40 3871244-5 1985 MPTP appeared to inhibit MAO-A in rat brain in vivo as determined by its antagonism of the inactivation of MAO-A by pargyline and by its antagonism of the increase in dopamine metabolites resulting from the administration of Ro 4-1284, a dopamine releaser. Pargyline 116-125 monoamine oxidase A Rattus norvegicus 25-30 3871244-5 1985 MPTP appeared to inhibit MAO-A in rat brain in vivo as determined by its antagonism of the inactivation of MAO-A by pargyline and by its antagonism of the increase in dopamine metabolites resulting from the administration of Ro 4-1284, a dopamine releaser. Pargyline 116-125 monoamine oxidase A Rattus norvegicus 107-112 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 41-58 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 60-63 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 213-218 6493360-6 1984 On the other hand, after chronic administration of pargyline (10 mg X kg-1), a preferential type B MAO inhibitor, the hypotension and bradycardia caused by clonidine were differently affected. Pargyline 51-60 monoamine oxidase A Rattus norvegicus 99-102 6493360-9 1984 Pargyline, that preferentially inhibits type B MAO, reduces only the bradycardia induced by clonidine. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 47-50 6421606-11 1984 stimulated the accumulation of 3-methoxytyramine and normetanephrine following monoamine oxidase (MAO) inhibition with pargyline. Pargyline 119-128 monoamine oxidase A Rattus norvegicus 79-96 6421606-11 1984 stimulated the accumulation of 3-methoxytyramine and normetanephrine following monoamine oxidase (MAO) inhibition with pargyline. Pargyline 119-128 monoamine oxidase A Rattus norvegicus 98-101 6542783-4 1984 In contrast to amitriptyline and pargyline pirlindole inhibited the MAO with tryptamine as a substrate in the brain 100 times (2.49 X 10(-7) mol/l) and in the heart nearly 1000 times (3.42 X 10(-8) mol/l) more than with phenylethylamine as a substrate (5.21 and 5.99 X 10(-5) mol/l, respectively). Pargyline 33-42 monoamine oxidase A Rattus norvegicus 68-71 6542783-5 1984 These results show that amitriptyline and pargyline are relatively selective inhibitors of MAO B, whereas pirlindole blocks the A-form of MAO much stronger than MAO B. Pargyline 42-51 monoamine oxidase A Rattus norvegicus 91-94 6092815-7 1984 These findings were reproduced by subacute administration of pargyline, a MAO inhibitor. Pargyline 61-70 monoamine oxidase A Rattus norvegicus 74-77 6514013-2 1984 Inhibition of monoamine oxidase (MAO) (by pretreatment of the animals with pargyline) increased the formation of O-methylated metabolites by nearly that amount by which the formation of deaminated metabolites declined; hence, catechol-O-methyl transferase (COMT) seemed to be able to nearly fully compensate for the loss of MAO activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 14-31 6514013-2 1984 Inhibition of monoamine oxidase (MAO) (by pretreatment of the animals with pargyline) increased the formation of O-methylated metabolites by nearly that amount by which the formation of deaminated metabolites declined; hence, catechol-O-methyl transferase (COMT) seemed to be able to nearly fully compensate for the loss of MAO activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 33-36 6514013-2 1984 Inhibition of monoamine oxidase (MAO) (by pretreatment of the animals with pargyline) increased the formation of O-methylated metabolites by nearly that amount by which the formation of deaminated metabolites declined; hence, catechol-O-methyl transferase (COMT) seemed to be able to nearly fully compensate for the loss of MAO activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 324-327 6542783-1 1984 The inhibition of monoamine oxidase (MAO) A and B by amitriptyline, pargyline and pirlindole was measured in heart and brain homogenates of rats with tryptamine and beta-phenylethylamine as substrates. Pargyline 68-77 monoamine oxidase A Rattus norvegicus 18-43 7150951-1 1982 Administration of the MAO-inhibitor pargyline resulted in an increase of dopamine (DA) and an exponential decrease of the metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in various rat brain areas. Pargyline 36-45 monoamine oxidase A Rattus norvegicus 22-25 6856953-2 1983 antagonized the inactivation of MAO by pargyline as measured by direct enzyme assays in brain homogenates and by accumulation of hypothalamic catecholamines. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 32-35 6847697-1 1983 [3H]Pargyline-labeled polypeptides associated with the A and B types of monoamine oxidase (MAO) activity in two rat cell lines were compared by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Pargyline 4-13 monoamine oxidase A Rattus norvegicus 91-94 6650186-3 1983 Serotonin turnover, measured by serotonin accumulation induced by the MAO inhibitor pargyline, decreased in the mesencephalon. Pargyline 84-93 monoamine oxidase A Rattus norvegicus 70-73 6856588-2 1983 As a first step, placental MAO content and its sensitivity to inhibition by pargyline were assessed in incubation studies of homogenates as well as during perfusion, taking rat liver as reference. Pargyline 76-85 monoamine oxidase A Rattus norvegicus 27-30 6856588-4 1983 MAO inhibition by pargyline significantly reduced the NA clearance from maternal to fetal circulation. Pargyline 18-27 monoamine oxidase A Rattus norvegicus 0-3 6401800-10 1983 Indomethacin (2 x 10(-4) M), catalase (50 micrograms/ml), and pargyline (2 x 10(-4) M) eliminated the MAO-dependent mitochondrial synthesis of PG endoperoxides. Pargyline 62-71 monoamine oxidase A Rattus norvegicus 102-105 6817759-0 1982 The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Pargyline 130-139 monoamine oxidase A Rattus norvegicus 42-73 6131854-3 1982 2) When it was measured by the accumulation of 3-methoxytyramine in the neostriatum and limbic forebrain of pargyline (MAO inhibitor)-pretreated rats, lisuride at the low dosage caused the inhibition of not only the spontaneous release of dopamine from the nerve terminal to the synaptic cleft, but also the release induced with methamphetamine. Pargyline 121-130 monoamine oxidase A Rattus norvegicus 132-135 6808207-7 1982 The titration experiment of MAO by pargyline suggests that the decrease of MAO activity, in vitro, is mainly due to the decrease of active MAO molecules in these mitochondrial preparations from livers of rats ingesting 3"-Me-DAB. Pargyline 35-44 monoamine oxidase A Rattus norvegicus 28-31 7127078-3 1982 Des-Tyr1-a-endorphin (beta-endorphin2-16; DTaE), on the other hand, inhibits the accumulation of serotonin following MAO-inhibition by pargyline in all 3 brain regions, while, in addition to causing a transient reduction in the serotonin concentration of the raphe area, it decreases the serotonin concentration of the mediobasal hypothalamus. Pargyline 135-144 monoamine oxidase A Rattus norvegicus 117-120 6123960-3 1982 In contrast pargyline, which only partially inhibited MAO-A, caused only a nonsignificant (7%) change in rat cortical beta-receptor binding. Pargyline 12-21 monoamine oxidase A Rattus norvegicus 54-59 6808207-7 1982 The titration experiment of MAO by pargyline suggests that the decrease of MAO activity, in vitro, is mainly due to the decrease of active MAO molecules in these mitochondrial preparations from livers of rats ingesting 3"-Me-DAB. Pargyline 35-44 monoamine oxidase A Rattus norvegicus 75-78 6808207-7 1982 The titration experiment of MAO by pargyline suggests that the decrease of MAO activity, in vitro, is mainly due to the decrease of active MAO molecules in these mitochondrial preparations from livers of rats ingesting 3"-Me-DAB. Pargyline 35-44 monoamine oxidase A Rattus norvegicus 75-78 6125331-5 1982 The administration of pargyline, a MAO inhibitor, which increased brain octopamine, resulted in a reduction of systolic blood pressure; and this decrease was greater after administration of octopamine precursors and PEA. Pargyline 22-31 monoamine oxidase A Rattus norvegicus 35-38 7098495-3 1982 The method clearly showed that clorgyline (a preferential type A inhibitor) preferentially inhibited rat heart MAO; whereas pargyline (a preferential type B inhibitor) preferentially inhibited mouse heart MAO. Pargyline 124-133 monoamine oxidase A Rattus norvegicus 205-208 6279462-1 1982 Inhibition of pineal monoamine oxidase (MAO) activity either by harmine or pargyline in adult male Sprague-Dawley rats housed in a 12 : 12 LD cycle resulted in increase pineal N-acetyltransferase (NAT) activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 21-38 6279462-1 1982 Inhibition of pineal monoamine oxidase (MAO) activity either by harmine or pargyline in adult male Sprague-Dawley rats housed in a 12 : 12 LD cycle resulted in increase pineal N-acetyltransferase (NAT) activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 40-43 6174485-6 1982 Omission of substrate from the incubation medium or pre-incubation with pargyline, a specific MAO inhibitor, drastically reduced the amount of deposits. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 94-97 7326580-2 1981 Some animals were also given the monoamine oxidase (MAO) inhibitor pargyline at designated times 10-40 min prior to sacrifice. Pargyline 67-76 monoamine oxidase A Rattus norvegicus 52-55 6104592-1 1980 The administration of pargyline to normal rats enhanced the adrenal catecholamines noradrenaline + adrenaline content, tyrosine hydroxylase (TH) and catechol -0-methyl transferase (COMT) activity together with a reduction in monoamine oxidase (MAO) activity. Pargyline 22-31 monoamine oxidase A Rattus norvegicus 225-242 7337495-7 1981 Pargyline, at a dose which significantly inhibited MAO and increased brain stem norepinephrine and dopamine levels, reduced the magnitude of the shock bradycardia. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 51-54 6784898-0 1981 Studies on the pargyline-binding site of different types of monoamine oxidase. Pargyline 15-24 monoamine oxidase A Rattus norvegicus 60-77 6784898-3 1981 The [3H]pargyline-MAO adducts were isolated and hydrolyzed by proteolytic enzymes, and the labelled peptides (pargyline-binding sites) separated and compared by paper chromatography and by paper electrophoresis at various pH values. Pargyline 8-17 monoamine oxidase A Rattus norvegicus 18-21 6784898-8 1981 It is concluded that the primary structures immediately surrounding the pargyline-binding sites are identical for both type A and type B MAO in these tissues. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 137-140 7335950-3 1981 Thus, incubation of DIP (10(-4) M) with rat liver mitochondria for 90 min demonstrated 74.8 +/- 4.1% metabolism which was almost completely blocked by the MAO inhibitor pargyline (10(-5) M). Pargyline 169-178 monoamine oxidase A Rattus norvegicus 155-158 6104592-1 1980 The administration of pargyline to normal rats enhanced the adrenal catecholamines noradrenaline + adrenaline content, tyrosine hydroxylase (TH) and catechol -0-methyl transferase (COMT) activity together with a reduction in monoamine oxidase (MAO) activity. Pargyline 22-31 monoamine oxidase A Rattus norvegicus 244-247 6785574-3 1980 Acetylenic amines as exemplified by clorgyline, deprenyl and pargyline are called "suicide inhibitors" because an irreversible inhibitor is formed by the action of MAO from a relatively innocuous compound which acts as a substrate. Pargyline 61-70 monoamine oxidase A Rattus norvegicus 164-167 6785574-7 1980 A comparison of the inhibitory effects of clorgyline, deprenyl and pargyline on liver enzyme preparations from bovine or rat have confirmed our expectation that these irreversible inactivators form the same type of adduct with the cysteinyl-flavin active site of MAO "type A" and "type B", and that binding is stoichiometric at the N-5 of the covalently bound flavin in a flavocyanine linkage. Pargyline 67-76 monoamine oxidase A Rattus norvegicus 263-266 523336-7 1979 This action of viloxazine was abolished by cyproheptadine but potentiated by pargyline, an inhibitor of MAO. Pargyline 77-86 monoamine oxidase A Rattus norvegicus 104-107 477738-1 1979 The monoamine oxidase (MAO) inhibitor pargyline induced a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats. Pargyline 38-47 monoamine oxidase A Rattus norvegicus 4-21 477738-1 1979 The monoamine oxidase (MAO) inhibitor pargyline induced a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats. Pargyline 38-47 monoamine oxidase A Rattus norvegicus 23-26 573894-2 1979 Serotonin (5-HT) agonists, L-tryptophan or 5-hydroxytryptophan and a MAO inhibitor, pargyline, suppressed the APO-induced aggressiveness. Pargyline 84-93 monoamine oxidase A Rattus norvegicus 69-72 499103-1 1979 Rat thyroid monoamine oxidase (MAO) was inhibited by the non-hydrazine derivatives paragyline and tranylcypromine to a higher degree than the hydrazine derivative iproniazide. Pargyline 83-93 monoamine oxidase A Rattus norvegicus 12-29 499103-1 1979 Rat thyroid monoamine oxidase (MAO) was inhibited by the non-hydrazine derivatives paragyline and tranylcypromine to a higher degree than the hydrazine derivative iproniazide. Pargyline 83-93 monoamine oxidase A Rattus norvegicus 31-34 1012333-3 1976 In rats treated with pargyline (50 mg/kg s.c.), the half-lives of recovery of striatal MAO activity and normal endogenous contents of homovanillic and 3,4-dihydroxyphenylacetic acids in striatum ranged from 9 to 14 days. Pargyline 21-30 monoamine oxidase A Rattus norvegicus 87-90 673014-13 1978 Inhibition of monoamine oxidase (MAO) by pargyline increased the extraneuronal formation of NMN; MAO and catechol-O-methyl transferase (COMT) appear to be contained in the same extraneuronal compartment. Pargyline 41-50 monoamine oxidase A Rattus norvegicus 14-31 673014-13 1978 Inhibition of monoamine oxidase (MAO) by pargyline increased the extraneuronal formation of NMN; MAO and catechol-O-methyl transferase (COMT) appear to be contained in the same extraneuronal compartment. Pargyline 41-50 monoamine oxidase A Rattus norvegicus 33-36 21126-6 1977 At 100% oxygen concentration, harmaline showed the most potent inhibition of MAO activity in the liver when serotonin served as substrate, while inhibitions of the MAO activity by pargyline and pheniprazine were weak. Pargyline 180-189 monoamine oxidase A Rattus norvegicus 164-167 21126-9 1977 Pargyline revealed a noncompetitive inhibition to MAO activity in liver and brain with tyramine and serotonin as substrate, harmaline a competitive inhibition to MAO activity in liver and brain with tyramine as substrate, while noncompetitive inhibition to MAO activity in liver and brain was evident when serotonin was used as the substrate. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 50-53 12389-8 1976 The pI curves for inhibition of MAO activity by harmine, pargyline and iproniazid were similar and almost the same pI 50 values for the respective inhibitors were obtained with the two substrates. Pargyline 57-66 monoamine oxidase A Rattus norvegicus 32-35 21126-5 1977 At 100% oxygen concentration, pargyline showed the most potent inhibition of MAO activity in liver mitochondria with tyramine as substrate, but inhibitions caused by pheniprazine and harmaline were not remarkable. Pargyline 30-39 monoamine oxidase A Rattus norvegicus 77-80 1012333-6 1976 Recovery from this effect of pargyline, however, was more rapid with a half-life of 15-19 h. Similar changes were observed when 3H-DOPA or 3H-dopamine was injected intracisternally, indicating that the phenomenon did not take place in the cerebral blood capillary walls, which are known to contain DOPA decarboxylase and MAO activities. Pargyline 29-38 monoamine oxidase A Rattus norvegicus 321-324 1012333-8 1976 was 3H-homovanillic acid, which was strongly reduced 2 h after pargyline, but normalized after 24 h of pretreatment with the MAO inhibitor. Pargyline 63-72 monoamine oxidase A Rattus norvegicus 125-128 1012333-10 1976 Moreover, in an experiment in which the animals were pretreated with pargyline at various times up to 21 days, a second injection of the MAO inhibitor 1.5 h before 3H-DOPA restored the increase in 3H-DA + 3H-MT observed with a single treatment with pargyline 1.5 h before the labelled amino acid. Pargyline 69-78 monoamine oxidase A Rattus norvegicus 137-140 1012333-10 1976 Moreover, in an experiment in which the animals were pretreated with pargyline at various times up to 21 days, a second injection of the MAO inhibitor 1.5 h before 3H-DOPA restored the increase in 3H-DA + 3H-MT observed with a single treatment with pargyline 1.5 h before the labelled amino acid. Pargyline 249-258 monoamine oxidase A Rattus norvegicus 137-140 1012333-12 1976 The threshold dose of pargyline for producing the short-term effect was about 10 times higher than that for an overall MAO (DA deaminating) inhibition. Pargyline 22-31 monoamine oxidase A Rattus norvegicus 119-122 1012333-14 1976 The data reported suggest the existence of a small portion of an additional form of MAO with a rapid turnover and with a marked capacity to deaminate dopamine or methoxytyramine, and a greater resistance to inhibition by pargyline than cerebral MAO in general. Pargyline 221-230 monoamine oxidase A Rattus norvegicus 84-87 956156-3 1976 The disappearance of PEA was completely inhibited by pargyline, a potent inhibitor of MAO. Pargyline 53-62 monoamine oxidase A Rattus norvegicus 86-89 33214844-4 2020 PET imaging studies in rats demonstrated that both [11C]COU and [11C]PHXY exhibit retention in cardiac tissues that can be blocked by pretreatment with the MAO inhibitors deprenyl (MAO-B) and pargyline (MAO-A and -B). Pargyline 192-201 monoamine oxidase A Rattus norvegicus 156-159 1143390-0 1975 Proceedings: Age dependent recovery of rat brain MAO activity after administration of a single dose of iproniazid and pargyline. Pargyline 118-127 monoamine oxidase A Rattus norvegicus 49-52 1116620-5 1975 Pargyline possibly acts by decreasing MAO levels which, in turn, may increase potentially damaging amines which may be responsible for the testicular damage. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 38-41 33214844-4 2020 PET imaging studies in rats demonstrated that both [11C]COU and [11C]PHXY exhibit retention in cardiac tissues that can be blocked by pretreatment with the MAO inhibitors deprenyl (MAO-B) and pargyline (MAO-A and -B). Pargyline 192-201 monoamine oxidase A Rattus norvegicus 203-215 21341713-0 2011 Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis. Pargyline 108-117 monoamine oxidase A Rattus norvegicus 22-48 26953687-4 2016 The effect of local administration of a MAO inhibitor, pargyline, was investigated. Pargyline 55-64 monoamine oxidase A Rattus norvegicus 40-43 26780349-9 2016 5-MeO-DMT (1mg/kg) had no effect on PPI when tested 45-min post-injection but disrupted PPI in animals pretreated with the MAO-A inhibitor clorgyline or the MAO-A/B inhibitor pargyline. Pargyline 175-184 monoamine oxidase A Rattus norvegicus 157-162 23196068-10 2013 The MAO inhibitor, pargyline, also attenuated cell death and ROS after l-dopa treatment. Pargyline 19-28 monoamine oxidase A Rattus norvegicus 4-7 25637699-6 2015 Monoamine aldehyde mediation of the oligomerization was assessed using the MAO inhibitor, pargyline. Pargyline 90-99 monoamine oxidase A Rattus norvegicus 75-78 19542488-11 2009 When 10 microM 5-HT was used, an additional hypertrophic response, prevented by the MAO inhibitors pargyline and RO 41-1049, was observed. Pargyline 99-108 monoamine oxidase A Rattus norvegicus 84-87 18322152-4 2008 In rats treated with the monoamine oxidase-A (MAO-A) inhibitor pargyline to prevent 5-HT metabolism, basal 5-HT levels were higher in veins than in arteries. Pargyline 63-72 monoamine oxidase A Rattus norvegicus 25-44 18322152-4 2008 In rats treated with the monoamine oxidase-A (MAO-A) inhibitor pargyline to prevent 5-HT metabolism, basal 5-HT levels were higher in veins than in arteries. Pargyline 63-72 monoamine oxidase A Rattus norvegicus 46-51 18539478-5 2008 However, combined treatment of this lower dose of S with pargyline inhibited SSAO, MAO, energy intake, weight gain and fat deposition. Pargyline 57-66 monoamine oxidase A Rattus norvegicus 83-86 17977742-7 2007 P+S treatments abolished MAO and SSAO activities in any tested tissue. Pargyline 0-3 monoamine oxidase A Rattus norvegicus 25-28 17977742-11 2007 Although our results did not directly demonstrate that amines are able to spontaneously produce in vivo the insulin-like effects described in vitro, we propose that P+S-induced reduction of fat deposition results from decreased food intake and from impaired MAO- and SSAO-dependent lipogenic and antilipolytic actions of endogenous or alimentary amines. Pargyline 165-168 monoamine oxidase A Rattus norvegicus 258-261 16754787-5 2006 In all of the 5-HT-uptake studies, we used arteries isolated from rats treated with the monoamine oxidase-A inhibitor pargyline to minimize 5-HT metabolism. Pargyline 118-127 monoamine oxidase A Rattus norvegicus 88-107 17912044-3 2007 This study examined the effects of three MAOIs (phenelzine, clorgyline and pargyline) with varying selectivity for MAOA and MAOB in the nicotine drug discrimination procedure in rats. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 115-119 17400208-3 2007 The irreversible and non-selective MAO inhibitor pargyline, and the reversible and selective MAO-A inhibitor clorgyline, produced increases in 5-HT syndrome in the 5-HTP-treated rats, while subchronic co-administration of imipramine partly intensified and partly attenuated the syndrome, whereas milnacipran only attenuated the syndrome. Pargyline 49-58 monoamine oxidase A Rattus norvegicus 35-38 15864503-5 2005 Inhibition of MAO (pargyline 1 mM) significantly increased the basal content of DA and the percentage of the added non-metabolised DA (to 95+/-10%) in PCT but had no effect on MTAL or MCD. Pargyline 19-28 monoamine oxidase A Rattus norvegicus 14-17 15703274-7 2005 In contrast, they were extensively (>80%) prevented by the amine uptake inhibitor imipramine, the MAO inhibitor pargyline and the MEK inhibitor PD 98059. Pargyline 115-124 monoamine oxidase A Rattus norvegicus 101-104 15167270-4 2004 5-HT and the metabolite 5-hydroxyindole acetic acid (5-HIAA) were detected in aorta, carotid, and superior mesenteric arteries using HPLC; the MAOA inhibitor pargyline significantly increased (over 400%) arterial 5-HT concentration. Pargyline 158-167 monoamine oxidase A Rattus norvegicus 143-147 15075350-4 2004 Pargyline and semicarbazide, specific inhibitors of MAO and SSAO, respectively, canceled this negative effect of MAO substrates on NOS2 expression. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 52-55 15075350-4 2004 Pargyline and semicarbazide, specific inhibitors of MAO and SSAO, respectively, canceled this negative effect of MAO substrates on NOS2 expression. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 113-116 12039844-5 2002 Rat pretreatment with the irreversible MAO inhibitor pargyline resulted in the following: i) prevented H2O2 production and lipid peroxidation; ii) decreased tubular cell apoptosis and necrosis, measured by TUNEL staining and histomorphological criteria; and iii) increased tubular cell proliferation as determined by proliferating cell nuclear antigen expression. Pargyline 53-62 monoamine oxidase A Rattus norvegicus 39-42 11453370-10 2001 These results indicate that near total inhibition of MAO-A by clorgyline and pargyline as assessed by MAO activity measurement induces an increase in locomotor activity but that inhibition of MAO-A or MAO-B, either alone or combined, does not facilitate spatial learning in adult rats. Pargyline 77-86 monoamine oxidase A Rattus norvegicus 53-58 12031549-7 2002 Treatments either with the antioxidant alpha-tocopherol acetate or the MAO inhibitor pargyline, given daily for 7 days after lesion, partially prevented the 40 microg MPP(+)-induced inhibition of DA uptake. Pargyline 85-94 monoamine oxidase A Rattus norvegicus 71-74 12091466-3 2002 Inhibition was prevented in the presence of pargyline and clorgyline demonstrating that mitochondrial inhibition arose from products formed following MAO metabolism and could include hydrogen peroxide (H(2) O(2) ), hydroxyl radical, oxidized glutathione (GSSG) or glutathione-protein mixed disulfides (PrSSG). Pargyline 44-53 monoamine oxidase A Rattus norvegicus 150-153 12172644-6 2002 The MAO inhibitors clorgyline (50 mM) and pargyline (500 mM) completely protect against MPT induction by 100 mM tyramine but also inhibit the phenomenon, although with different efficacy, when it is induced by 100 mM Ca2+ in the absence of tyramine. Pargyline 42-51 monoamine oxidase A Rattus norvegicus 4-7 10996452-3 2000 A low dose of pargyline (10mg/kg) produced significantly higher inhibition of MAO-A in the alcoholised rats, whereas the degree of MAO-B inhibition was the same in both groups. Pargyline 14-23 monoamine oxidase A Rattus norvegicus 78-83 10996452-5 2000 Since chronic ethanol feeding reduced the content of reversible endogenous MAO inhibitor, tribulin, higher pargyline-induced inhibition of MAO-A in alcoholised rats may stem from a tribulin deficit. Pargyline 107-116 monoamine oxidase A Rattus norvegicus 75-78 10996452-5 2000 Since chronic ethanol feeding reduced the content of reversible endogenous MAO inhibitor, tribulin, higher pargyline-induced inhibition of MAO-A in alcoholised rats may stem from a tribulin deficit. Pargyline 107-116 monoamine oxidase A Rattus norvegicus 139-144 10081977-1 1999 The present study investigated in vivo the kinetics of the changes in rat striatal extracellular concentrations of dopamine (DA), and its monoamine oxidase (MAO)-derived metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), following administration either of nitric oxide (NO) synthase inhibitors 7-nitroindazole (7-NI) and N(omega)-nitro-L-arginine methyl ester (L-NAME) or of the widely used MAO inhibitor pargyline. Pargyline 405-414 monoamine oxidase A Rattus norvegicus 157-160 10719089-4 2000 Rats treated with intraperitoneal injections of pargyline, an MAO inhibitor, showed significantly stronger DA- and NA-staining intensities in LC neurons compared to normal rats. Pargyline 48-57 monoamine oxidase A Rattus norvegicus 62-65 11225512-2 2000 Administration of pargyline (10 mg/kg, s.c.) produced significantly higher inhibition of MAO-A in alcoholised rats, whereas MAO-B inhibition did not differ from that observed in control animals. Pargyline 18-27 monoamine oxidase A Rattus norvegicus 89-94 11225512-3 2000 The concentration-response curve for the inhibition of brain mitochondrial MAO-A and MAO-B by pargyline in vitro did not reveal higher sensitivity of MAO from alcoholised rats to pargyline. Pargyline 94-103 monoamine oxidase A Rattus norvegicus 75-80 11225512-3 2000 The concentration-response curve for the inhibition of brain mitochondrial MAO-A and MAO-B by pargyline in vitro did not reveal higher sensitivity of MAO from alcoholised rats to pargyline. Pargyline 94-103 monoamine oxidase A Rattus norvegicus 75-78 10320000-1 1999 The present study investigated in vivo the kinetic of the changes in rat striatal extracellular concentrations of dopamine (DA), and its monoamine oxidase (MAO)-derived metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), following administration either of nitric oxide (NO) synthase (NOS) inhibitors 7-nitroindazole (7-NI) and Nomega-nitro-l-arginine methyl ester (L-NAME) or of the widely used MAO inhibitor pargyline. Pargyline 408-417 monoamine oxidase A Rattus norvegicus 156-159 10208295-8 1999 After the acute administration of both deprenyl and pargyline, a significant decrease in the MAO activities of both young (P=0.0002 for each) and aging rats (P=0.0002 for deprenyl and P=0.0001 for pargyline) were observed. Pargyline 52-61 monoamine oxidase A Rattus norvegicus 93-96 10208295-8 1999 After the acute administration of both deprenyl and pargyline, a significant decrease in the MAO activities of both young (P=0.0002 for each) and aging rats (P=0.0002 for deprenyl and P=0.0001 for pargyline) were observed. Pargyline 197-206 monoamine oxidase A Rattus norvegicus 93-96 10208305-3 1999 For this purpose, the locus coeruleus was superfused in the absence and in the presence of the MAO inhibitor pargyline. Pargyline 109-118 monoamine oxidase A Rattus norvegicus 95-98 8820177-3 1996 As expected, after pargyline administration tissue concentrations of 5-HT, noradrenaline (NA) and dopamine (DA) were markedly increased due to MAO inhibition with a concomitant decrease of the metabolites 5-hydroxyindole-3-acetic acid and homovanillic acid. Pargyline 19-28 monoamine oxidase A Rattus norvegicus 143-146 10025842-6 1999 In the first approach, oxidation of PHEN by MAO was inhibited at the enzymatic level with the MAO inhibitor pargyline. Pargyline 108-117 monoamine oxidase A Rattus norvegicus 44-47 10025842-6 1999 In the first approach, oxidation of PHEN by MAO was inhibited at the enzymatic level with the MAO inhibitor pargyline. Pargyline 108-117 monoamine oxidase A Rattus norvegicus 94-97 10025842-10 1999 Inhibition of MAO activity with either pargyline or di-deuterium substitution did not significantly alter this rate. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 14-17 9324239-2 1997 The influence of isatin on the degree of irreversible MAO inhibition by phenelzine and pargyline has been studied in vitro and in vivo experiments. Pargyline 87-96 monoamine oxidase A Rattus norvegicus 54-57 8912226-4 1996 The possibility that these discrepant results were due to metabolism of the receptor ligands was investigated by increasing the concentration of the monoamine oxidase (MAO) inhibitor, pargyline. Pargyline 184-193 monoamine oxidase A Rattus norvegicus 149-166 8912226-4 1996 The possibility that these discrepant results were due to metabolism of the receptor ligands was investigated by increasing the concentration of the monoamine oxidase (MAO) inhibitor, pargyline. Pargyline 184-193 monoamine oxidase A Rattus norvegicus 168-171 8813364-3 1996 In L-DOPA/carbidopa-injected rats that were pretreated with an intraperitoneal injection of a MAO inhibitor, pargyline, when compared with the L-DOPA/carbidopa-injected rats without the pargyline pretreatment, neurons of the cluster of the DR became much darker in dopamine staining. Pargyline 109-118 monoamine oxidase A Rattus norvegicus 94-97 8852930-4 1996 The inhibitory effect of monoamine oxidase (MAO) activity by pargyline was maximal at 1.5 months. Pargyline 61-70 monoamine oxidase A Rattus norvegicus 25-42 8852930-4 1996 The inhibitory effect of monoamine oxidase (MAO) activity by pargyline was maximal at 1.5 months. Pargyline 61-70 monoamine oxidase A Rattus norvegicus 44-47 8821544-2 1996 2 The non-specific MAO inhibitor, pargyline, superfused at a concentration of 10-100 microM, decreased or abolished the spontaneous firing discharge of the principal neurons in the subtantia nigra pars compacta and ventral tegmental area. Pargyline 34-43 monoamine oxidase A Rattus norvegicus 19-22 8528552-8 1995 The remaining 30-40% was displaced specifically by the monoamine oxidase A inhibitors, clorgyline and pargyline. Pargyline 102-111 monoamine oxidase A Rattus norvegicus 55-74 8868138-3 1995 In animals receiving pargyline (a MAO-A inhibitor which blocks 5-HT catabolism), AS-8 markedly enhanced 5-HT accumulation in the brains of rats and mice, but not chicks. Pargyline 21-30 monoamine oxidase A Rattus norvegicus 34-39 7478301-3 1995 In the present study, release of the false transmitter serotonin from the dopaminergic nerve terminals was studied by loading the neurons in vivo with serotonin precursor L-tryptophan and MAO inhibitor pargyline, which results in accumulation of false transmitter serotonin. Pargyline 202-211 monoamine oxidase A Rattus norvegicus 188-191 7853182-6 1995 Moreover, [3H]-idazoxan binding was also competed for by several MAO inhibitors (MAOI) that are not imidazoline or guanidinium derivatives such as tranylcypromine, harmaline, clorgiline and pargyline. Pargyline 190-199 monoamine oxidase A Rattus norvegicus 65-68 9101254-9 1995 The oxidant scavenger dimethylthiourea (DMTU) and the monoamine oxidase (MAO) inhibitor pargyline, administered to CO poisoned rats after HBO at 2.5 ATA, diminished 2,3-DHBA production in both subcellular compartments. Pargyline 88-97 monoamine oxidase A Rattus norvegicus 54-71 9101254-9 1995 The oxidant scavenger dimethylthiourea (DMTU) and the monoamine oxidase (MAO) inhibitor pargyline, administered to CO poisoned rats after HBO at 2.5 ATA, diminished 2,3-DHBA production in both subcellular compartments. Pargyline 88-97 monoamine oxidase A Rattus norvegicus 73-76 7830076-4 1995 Furthermore, clorgyline, a selective inhibitor of monoamine oxidase type A, and pargyline, an inhibitor of both monoamine oxidase types A and B, both did not have an effect on L-DOPA toxicity. Pargyline 80-89 monoamine oxidase A Rattus norvegicus 112-143 11224327-5 1995 Chronic administration (two injections/day for 8 weeks) with a non-selective (i.e. MAO-A and MAO-B inhibiting) dose of pargyline (15mg/kg) resulted in a time-dependent increase in punished responding. Pargyline 119-128 monoamine oxidase A Rattus norvegicus 83-88 8121637-2 1993 Displacement of the [3H]pargyline binding on MAO-A (L(-)-deprenyl suppressed binding to MAO-B) by harman, 1-methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) revealed IC50 values of 250 +/- 100 nM, 3.1 +/- 0.8 microM, and 5.1 +/- 0.4 microM, respectively. Pargyline 24-33 monoamine oxidase A Rattus norvegicus 45-50 7931249-7 1994 At these doses, befloxatone inhibited totally and selectively MAO-A, pargyline inhibited totally MAO-A and MAO-B. Pargyline 69-78 monoamine oxidase A Rattus norvegicus 97-102 7931249-8 1994 Increases of tissue and extracellular concentrations of NA and 5HT were highest after Pargyline suggesting that both monoamines may be metabolized by MAO-A and MAO-B. Pargyline 86-95 monoamine oxidase A Rattus norvegicus 150-155 8385528-0 1993 Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain. Pargyline 71-80 monoamine oxidase A Rattus norvegicus 27-44 7682724-8 1993 The monoamine oxidase (MAO) inhibitors pargyline, i.p., and deprenyl, i.p., as well as the DA agonist apomorphine, i.p., decreased the catechol signal. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 4-21 7682724-8 1993 The monoamine oxidase (MAO) inhibitors pargyline, i.p., and deprenyl, i.p., as well as the DA agonist apomorphine, i.p., decreased the catechol signal. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 23-26 8462004-5 1993 In this study, rats treated with an MAO inhibitor (pargyline) or a nitric oxide synthase inhibitor (LNNA) were protected against O2-induced convulsions. Pargyline 51-60 monoamine oxidase A Rattus norvegicus 36-39 1757301-7 1991 Pargyline, administered 30 min before HBO, inhibited MAO by greater than 90%, prevented ATZ inhibition of catalase activity during HBO, and reversed the augmentation of CNS O2 toxicity by ATZ. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 53-56 1511517-2 1992 In this study, pregnant animals were pre-treated with the MAO inhibitor pargyline (200 mg/kg i.p. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 58-61 8482527-6 1993 Effects on basal outflow were not observed, when monoamine oxidase (MAO) was inhibited by pargyline. Pargyline 90-99 monoamine oxidase A Rattus norvegicus 49-66 8482527-6 1993 Effects on basal outflow were not observed, when monoamine oxidase (MAO) was inhibited by pargyline. Pargyline 90-99 monoamine oxidase A Rattus norvegicus 68-71 1358631-12 1992 The monoamine oxidase (MAO) inhibitor, pargyline (10-100 microM), did not significantly affect 5-HT-induced contraction. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 23-26 1309756-7 1992 Furthermore, reaction of either clorgyline or another mechanism-based inhibitor, pargyline, with the membrane-bound enzyme during ATP depletion inhibited the insertion of monoamine oxidase A when ATP was restored. Pargyline 81-90 monoamine oxidase A Rattus norvegicus 171-190 2039542-6 1991 After incubation with radioactively-labeled pargyline polyacrylamide-gel electrophoresis in the presence of sodium dodecyl sulphage (SDS-PAGE) showed the radioactivity to be associated with a peptide of approximate Mr 50,000, corresponding to the subunit of MAO. Pargyline 44-53 monoamine oxidase A Rattus norvegicus 258-261 2016753-5 1991 Inhibition of MAO activity with pargyline in vivo did not affect the pattern of IDPN- or DMAPN-induced toxicity. Pargyline 32-41 monoamine oxidase A Rattus norvegicus 14-17 2117053-13 1990 The nonselective MAO inhibitor pargyline caused similar but more pronounced alterations in these parameters. Pargyline 31-40 monoamine oxidase A Rattus norvegicus 17-20 2384758-10 1990 There was also a parallel between the capacity of clorgyline and pargyline, irreversible MAO inhibitors, to decrease the formation of the pyridinium species and their capacity to protect against the toxic actions of the tetrahydropyridines. Pargyline 65-74 monoamine oxidase A Rattus norvegicus 89-92 1682049-6 1991 Pargyline produced an increase in TH-like immunoreactivity and the disappearance of MAO activity. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 84-87 1700071-5 1990 5-HT oxidation to 5-HIAA is carried out principally by MAO-A, because clorgyline was more effective at inhibiting the production of 5-HIAA than was pargyline. Pargyline 148-157 monoamine oxidase A Rattus norvegicus 55-60 1700071-6 1990 Radioenzymatic determinations of MAO activity in cell homogenates supported these findings, because under these conditions clorgyline was 1,000-fold more effective than pargyline at inhibiting MAO activity toward 14C-labelled 5-HT. Pargyline 169-178 monoamine oxidase A Rattus norvegicus 193-196